Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Vitreoretinal Associates PA

Neither a doctor nor a teaching hospital

Research payments

$1,009,394

215 payments

Through program year 2025, Vitreoretinal Associates PA is reported as receiving $1,009,394 in research payments, across 215 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $31,387 8
2024 Research $426,030 166
2023 Research $195,378 17
2022 Research $53,654 8
2021 Research $98,333 13
2020 Research $97,016 2
2019 Research $107,597 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $629,319 192 payments
  2. Biogen, Inc. $269,742 9 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $79,260 11 payments
  4. AbbVie, Inc. $19,574 2 payments
  5. EyePoint Pharmaceuticals US, Inc. $11,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Mgt021 $325,837 128 payments
  2. A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) $112,388 3 payments
  3. A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa $107,597 1 payment
  4. Mgt-Rpgr-022 $83,656 5 payments
  5. A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular $68,267 22 payments
  6. A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration $50,378 5 payments
  7. BAY865321, HD 8mg, AMD - Ph 3 $46,388 7 payments
  8. A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects with X-Linked Retinitis Pigmentosa Previously Treated with Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study $42,457 4 payments
  9. BAY865321 HD 8mg AMD - Ph 3 $32,871 4 payments
  10. An Exploratory Study to Evaluate Photo aversion Endpoints and Validate Two Separate Instruments Used to Measure Photo aversion in Normally Sighted Participants and Participants With Confirmed Achromatopsia $31,174 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record